Skip to main content

CorMedix Inc.

For the period ended Dec 31, 2024. Filed Mar 25, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 25, 2025

CRMD$5.37-1.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 15. Exhibits, Financial Statement Schedules

1.Financial Statements. The following consolidated financial statements of CorMedix Inc. are filed as part of this Annual Report on Form 10-K:

Report of Independent Registered Public Accounting Firm (PCAOB ID # 688)F-2
Consolidated Balance Sheets as of December 31, 2024 and 2023F-3
Consolidated Statements of Operations and Comprehensive Income (Loss) Years Ended December 31, 2024 and 2023F-4
Consolidated Statements of Changes in Stockholders’ Equity Years Ended December 31, 2024 and 2023F-5
Consolidated Statements of Cash Flows Years Ended December 31, 2024 and 2023F-6
Notes to Consolidated Financial StatementsF-7
  1. Financial Statement Schedules. The Financial Statement Schedules have been omitted because of the absence of conditions under which they are required or because the required information, where material, is shown in the financial statements or notes thereto.

3.Exhibit Index. The following is a list of exhibits filed as part of this Annual Report on Form 10-K:

Exhibit Number · Description of Document · Registrant’s Form · Dated · Exhibit Number · Filed or Furnished Herewith
1.1At-the-Market Issuance Sales Agreement, dated August 12, 2021, by and among CorMedix Inc., Truist Securities, Inc. and JMP Securities LLC8-K08/12/20211.1
3.1Form of Amended and Restated Certificate of IncorporationS-1/A3/01/20103.3
3.2Certificate of Amendment to Amended and Restated Certificate of Incorporation, dated February 24, 2010S-1/A3/19/20103.5
3.3Second Amended and Restated Bylaws as amended October 8, 20208-K10/14/20203.1
3.4Certificate of Amendment to Amended and Restated Certificate of Incorporation, dated December 3, 201210-K3/27/20133.3
3.5Certificate of Amendment to Amended and Restated Certificate of Incorporation, dated August 9, 20178-K8/10/20173.1
3.6Certificate of Amendment to Amended and Restated Certificate of Incorporation, dated March 25, 20198-K3/25/20193.1
3.7Amended and Restated Certificate of Designation of Series C-3 Non-Voting Convertible Preferred Stock of CorMedix Inc., filed with the Delaware Secretary of State on September 15, 20148-K9/16/20143.16
Exhibit Number · Description of Document · Registrant’s Form · Dated · Exhibit Number · Filed or Furnished Herewith
3.8Second Amended and Restated Certificate of Designation of Series E Convertible Preferred Stock of CorMedix Inc., filed with the Delaware Secretary of State on September 5, 20198-K9/11/20193.2
3.9Certificate of Designation of Series G Convertible Preferred Stock of CorMedix Inc., filed with the Delaware Secretary of State on September 5, 20198-K9/11/20193.1
4.1Specimen of Common Stock CertificateS-1/A3/19/20104.1
4.2Form of Warrant issued on January 8, 2014.8-K1/09/20144.23
4.3Form of Series B Warrant to Purchase Common Stock of CorMedix Inc. issued on May 3, 20178-K5/03/20174.2
4.4Form of Underwriter’s Warrant to Purchase Common Stock of CorMedix Inc., issued May 3, 20178-K5/03/20174.3
4.5Description of Capital Stock of CorMedix Inc.10-K03/16/20204.5
4.6Form of Pre-Funded Warrant issued June 28, 20238-K06/30/20234.1
10.1*License and Assignment Agreement, dated as of January 30, 2008, between CorMedix Inc. and ND Partners LLCS-1/A12/31/200910.5
10.2+Form of Indemnification Agreement between CorMedix Inc. and each of its directors and executive officers10-Q5/15/202310.1
10.3**+Executive Employment Agreement, dated and effective May 11, 2020, between CorMedix Inc. and Matthew David10-K3/30/202110.10
10.4+Letter Agreement, dated and effective October 26, 2021, between CorMedix Inc. and Matthew David, M.D.8-K10/29/202110.1
10.5Form of Securities Purchase Agreement, dated November 17, 2017, between CorMedix Inc. and the investors signatory thereto8-K11/13/201710.1
10.6Backstop Agreement, dated November 9, 2017, between CorMedix Inc. and the investor named therein8-K11/13/201710.2
10.7Form of Registration Rights Agreement, dated November 9, 2017, by and between CorMedix Inc. and the investor named therein8-K11/13/201710.3
10.8Amendment No. 1, dated as of December 11, 2017, to Registration Rights Agreement, dated November 9, 2017, by and between CorMedix Inc. and the investor named therein8-K12/11/201710.1
10.9**+Executive Employment Agreement, dated and effective March 10, 2021, between CorMedix Inc. and Elizabeth Hurlburt8-K3/12/202110.1
10.10Securities Purchase Agreement, dated December 31, 2018, between CorMedix Inc. and the investor named therein8-K1/03/201910.1
10.11Securities Exchange Agreement, dated August 14, 2019, by and among CorMedix Inc. and the Existing Security holders listed on the Schedule of Holders thereto8-K8/15/201910.1
Exhibit NumberDescription of DocumentRegistrant’s FormDatedExhibit NumberFiled or Furnished Herewith
10.12Amended and Restated Registration Rights Agreement, dated as of September 6, 2019, by and among CorMedix Inc. and Manchester Securities Corp., and Elliot International, L.P. and Elliot Associates, L.P.8-K9/11/201910.1
10.13Amended and Restated 2019 Omnibus Stock Incentive PlanS-810/26/202299.1
10.14+2021 Executive Bonus Plan8-K12/23/202110.1
10.15+Executive Employment Agreement, dated March 16, 2022, between CorMedix Inc. and Joseph Todisco.8-K03/21/202210.2
10.16+Executive Employment Agreement, dated December 12, 2023, between CorMedix Inc. and Beth Zelnick Kaufman.X
10.17Amendment No. 1 to the Amended and Restated CorMedix Inc. 2019 Omnibus Stock Incentive Plan8-K11/21/202410.1
19.1Insider Trading Policies and ProceduresX
21.1List of Subsidiaries10-K3/27/201321.1
23.1Consent of Independent Registered Public Accounting FirmX
31.1Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.X
31.2Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002X
32.1***Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002X
32.2***Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002X
97.1Board Policy on Recouping Incentive Compensation10-K3/12/202497.1
101.INSInline XBRL Instance DocumentX
101.SCHInline XBRL Taxonomy Extension Schema Document.X
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document.X
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document.X
101.LABInline XBRL Taxonomy Extension Label Linkbase Document.X
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document.X
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).X
*Confidential treatment has been granted for portions of this document. The omitted portions of this document have been filed separately with the SEC.
**Portions of the exhibit have been omitted in reliance on Item 601(b)(10)(iv) of Regulation S-K.
***These certifications are furnished.
+Indicates management contract or compensation plan.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.